Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New agents for inhibiting EGF receptor-mediated abnormal cell growth

June 25, 1998

More telomerase inhibitors added to the Geron pipeline

June 25, 1998

Potent angiogenesis inhibitor AG-3340 profiled at NCI-EORTC symposium

June 24, 1998

Introgen Therapeutics acquires exclusive option to license PTEN gene

June 24, 1998

Phase II evaluation of carzelesin in NHL

June 24, 1998

Miproxifene phosphate, a promising treatment for breast cancer

June 24, 1998

Management strategy including hydroxyurea successful in unresectable meningioma

June 24, 1998

S-16020-2: a topoisomerase II inhibitor selective for renal cancers heads for phase II testing

June 24, 1998

Select Therapeutics signs agreement for cancer vaccine platform technology

June 24, 1998

Lilly presents results of first clinical trial evaluating the MDR modulator LY-335979

June 23, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...